(Total Views: 651)
Posted On: 10/20/2020 7:20:19 PM
Post# of 154896
Please punch a hole in my thinking if you disagree.
The advisory committee said to go forward without changing anything, so it's only a matter of enrolling 63 additional s/c patients to complete the trials requirement. With the addition of the UK patients (five locations) and the good vibes which should hasten enrollment in the USA, achieving this should be a fairly quick given.
The mortality timeline was changed from 28 days to 42 days. While the leronlimab/placebo mortality rate was already favorable at 28 days, divergence in favor of leronlimab is significantly amplified at 42 days.
All of the foregoing was based on what was stated by Cytodyn during the conference call. Keep in mind, Cytodyn is still blind as to the data, and, the info is what was inferred by the advisory committee. .
The advisory committee said to go forward without changing anything, so it's only a matter of enrolling 63 additional s/c patients to complete the trials requirement. With the addition of the UK patients (five locations) and the good vibes which should hasten enrollment in the USA, achieving this should be a fairly quick given.
The mortality timeline was changed from 28 days to 42 days. While the leronlimab/placebo mortality rate was already favorable at 28 days, divergence in favor of leronlimab is significantly amplified at 42 days.
All of the foregoing was based on what was stated by Cytodyn during the conference call. Keep in mind, Cytodyn is still blind as to the data, and, the info is what was inferred by the advisory committee. .
(5)
(0)
